Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The speakers extolled the benefits of telehealth while noting the challenges posed by a lack of high-speed Internet in some parts of the country.
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
Arkuda seeks to disrupt the usual progression of neurodegenerative disease with medicines developed by applying cutting-edge knowledge from the domains of lysosomal and microglial biology.
The London-based Financial Times reported that 83% of companies listed on stock exchanges over the past two years are now trading well below their initial public offering price.
kENUP had called the mRNA vaccine efforts in Africa “doomed to fail” since the project likely infringes on BioNTech and Moderna patents on the vaccine.
Shares of Alnylam Pharmaceuticals are sliding in morning trading despite the news that the company’s revenues grew by 83% in 2021 compared to the previous year.
Ardelyx has reported in a regulatory filing that the FDA sent an Appeal Denied Letter for its drug tenapanor, a therapeutic intended for chronic kidney disease.
Bayer joined in the $50 million Series A for San Francisco’s Indapta Therapeutics.
As AstraZeneca released its 2021 annual financial report, a BBC documentary suggested that the way scientists and politicians politicized its COVID-19 vaccine may have cost lives.
Recent research supports a link between vitamin D deficiency and severe COVID-19. Here’s a look.
It’s uncertain if the origins of COVID-19 will ever be determined, but the current top theories split about evenly between a lab leak from the Wuhan Institute of Virology and a natural evolution from bats to animals to humans at a Wuhan “wet market.”
The EUA request is based on the Phase II study that showed treatment with ensovibep reduced the viral load from the SARS-CoV-2 virus within eight days of use compared to placebo.